Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.35 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.35 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10102234 | 0.84 | DRD2 (0.43) | DRD2KDM4EALDH1A1 | |
| SCHEMBL10102360 | 0.83 | ALOX5 (0.44) | DRD2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL13880266 | 0.78 | DRD2 (0.46) | DRD2RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL13880445 | 0.78 | DRD2 (0.43) | DRD2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL13880648 | 0.75 | SMN1; SMN2 (0.39) | DRD2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL13766161 | 0.70 | DRD2 (0.46) | DRD2RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL7789933 | 0.70 | ALDH1A1 (0.46) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL6983448 | 0.70 | MAOA (0.39) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL7784188 | 0.70 | TRPM4 (0.44) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL10106883 | 0.69 | ACHE (0.51) | NPC1RAB9ASMN1; SMN2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8308995-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-11-13 | — | — | US | disclosed |
| US-8308995-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-11-13 | — | — | US | disclosed |
| EP-2275418-B1 | CHROMENE COMPOUND | TOKUYAMA CORP (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-20120138876-A1 | CHROMENE COMPOUND | KASAI SOKO (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120138876-A1 | CHROMENE COMPOUND | KASAI SOKO (JP) | 2012-06-07 | — | — | US | disclosed |
| US-8147726-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-04-03 | — | — | US | disclosed |
| US-8147726-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20110062396-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2011-03-17 | — | — | US | disclosed |
| US-20110062396-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120138876-A1 | CHROMENE COMPOUND | CHRM1, CBX8, CBX7 | DRD2 412/4885NPC1 1130/4885RAB9A 1112/4885 |
| US-20110062396-A1 | CHROMENE COMPOUND | CDYL, NR0B1, NR1H2 | DRD2 742/4885NPC1 809/4885RAB9A 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.